Phosphagenics begins manufacturing expansion
Australian company Phosphagenics has begun its programme for upscaling its manufacture of tocopheryl phosphates, the vital components of many of its pharmaceutical and nutraceutical products, with the construction of a new production plant in Melbourne.
Australian company Phosphagenics has begun its programme for upscaling its manufacture of tocopheryl phosphates, the vital components of many of its pharmaceutical and nutraceutical products, with the construction of a new production plant in Melbourne.
Expected to be commercially ready by the end of 2006, the A$500,000 facility will be a scaled-up version of a pilot plant used successfully in the initial development of Phosphagenics' proprietary phosphorylation process. On completion it will have an annual capacity of 100 tonnes of high purity tocopheryl phosphates (worth an estimated wholesale value of A$25m), although Phosphagenics does not expect to utilise all of this capacity "in the immediate future".
Ian Pattison, chief operating officer of Phosphagenics, said the new plant will demonstrate the company's "capability to manufacture on a commercial scale for current and future licensing partners" and allow it "to step up manufacturing output as the markets for Phosphagenics' products develop".